Kala Pharmaceuticals (KALA) Misses Q2 EPS by 316c
Tweet
Share
E-mailGet Alerts KALA Hot Sheet
Join SI Premium – FREE
Kala Pharmaceuticals (NASDAQ: KALA) reported Q2 EPS of ($3.16).
For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Li Ning Co. Ltd. (2331:HK) (LNNGF) to Neutral
- RBC Capital Downgrades GQG Partners Inc (GQG:AU) to Sector Perform
- Goldman Sachs Upgrades Drax Group Plc. (DRX:LN) (DRXGY) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
